Coronary risk stratification in HIV/AIDS patients treated with protease inhibitors

Authors

Keywords:

HIV/AIDS, coronary risk, chronic diseases

Abstract

Introduction: Between 2000 and 2018, new HIV/AIDS infections decreased by 37% and deaths related to the infection decreased by 45%; thanks to the antiretroviral treatment, 13.6 million lives were saved. In the mid-1990s, cases of myocardial infarction began to be reported in young patients infected with HIV/AIDS. Successful treatment of the disease has increased the prevalence of several chronic diseases, including cardiovascular diseases. In the developed world more than 25% of HIV patients are over 50 years old.

Objective: To stratify the risk of cardiovascular disease in HIV/AIDS patients who are treated with protease inhibitors associated with lipid markers in the province of Matanzas.

Method: An observational, analytical, cross-sectional study was carried out on HIV/AIDS patients from the province of Matanzas during the period from March to August 2020, in the clinical laboratory of the Clinical Surgical University Hospital Comandante Faustino Perez Hernandez.

Results: The cardiovascular risk associated with antiretroviral treatment was evaluated; dyslipidemia, sedentary lifestyle and hypertension are reported with higher incidence.

Conclusions: Cardiovascular risk factors were identified and their stratification was performed.

Downloads

Download data is not yet available.

References

1. Organización Mundial de la Salud. VIH y sida [Internet]. Ginebra: OMS; 2020 [citado 16/12/2020]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/hiv-aids

2. Grupo de expertos del Grupo de Estudio sobre Alteraciones Metabólicas (GEAM), de la Secretaría del Plan Nacional sobre el Sida (SPNS) y del Grupo de Estudio de Sida (GeSIDA). Documento de consenso sobre alteraciones metabólicas y riesgo cardiovascular en pacientes con infecciones por el VIH [Internet]. Madrid: Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; 2017 [citado 16/12/2020]. Disponible en: https://gesida-seimc.org/wp-content/uploads/2017/02/gesida-guiasclinicas-2017-Alteraciones_Metabolicas_y_RCV_VIH.pdf

3. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-934. DOI: 10.1016/j.jacc.2013.11.002.

4. Echevarría Bermúdez JP. Estudio Metabólico y Cardiovascular en una Cohorte de Pacientes Infectados por el VIH-1: Predisposición Genética, Aterosclerosis Subclínica y Eventos Coronarios [tesis en Internet]. Barcelona: Universidad Autónoma de Barcelona; 2015 [citado 16/12/2020]. Disponible en: https://www.tesisenred.net/bitstream/handle/10803/330366/jpeb1de1.pdf

5. Revueltas-Agüero M, Valdés-González Y, Serra-Larín S, et al. Estimación del riesgo cardiovascular en una población, según dos tablas predictivas. Arch Méd Camagüey [Internet]. 2020 [citado 16/03/2022];24(5):688-700. Disponible en: http://www.revistaamc.sld.cu/index.php/amc/article/view/7533

6. Centro Nacional de Información de Ciencias Médicas. Biblioteca Médica Nacional. Cardiopatía isquémica. Estadísticas mundiales. Factográfico salud [Internet]. 2019 [citado 16/03/2022];5(2): [aprox. 11 pantallas]. Disponible en: http://files.sld.cu/bmn/files/2019/02/factografico-de-salud-febrero-2019.pdf

7. Murillo Suárez AD, Veliz Castro T, Vargas López JM. Tiempo de adherencia a terapia antirretroviral y su asociación con parámetros bioquímicos en pacientes de la unidad de atención integral VIH/SIDA Manta 2018 [Internet]. Jipijapa: UNESUM; 2019 [citado 16/03/2022]. http://repositorio.unesum.edu.ec/handle/53000/1962

8. Bravo Remache AE. Antirretrovirales y perfil lipídico en pacientes con virus de inmunodeficiencia humana Hospital Baca Ortiz 2002-2015 [tesis en Internet]. Quito: Universidad Central del Ecuador; 2017 [citado 16/03/2022]. Disponible en: https://www.dspace.uce.edu.ec/entities/publication/4388ded4-c803-4827-803b-b67b364afcfa

9. Carvajal Alzate M, Roldán Tabares MD, Herrera Almanza L. Virus de inmunodeficiencia humana: hallazgos útiles en el diagnóstico, prevención y tratamiento. Enf Inf Microbiol [Internet]. 2019 [citado 16/03/2022];39(2):65-70. Disponible en: https://www.medigraphic.com/pdfs/micro/ei-2019/ei192e.pdf

10. ONUSIDA. Comunidades en el Centro. La respuesta al VIH en América Latina [Internet]. Ginebra: ONUSIDA; 2019 [citado 16/12/2020]. Disponible en: Disponible en: https://www.unaids.org/sites/default/files/media_asset/2019-global-AIDS-update_latin-america_es.pdf

11. Sánchez Álvarez ML, Guirado Cruz R, Alegret Rodríguez M. Estimación del riesgo cardiovascular en pacientes con VIH. Medicent Electrón [Internet]. 2018 [citado 17/01/2022];22(4). Disponible en: https://www.medigraphic.com/pdfs/medicentro/cmc-2018/cmc184c.pdf

12. Torres-Peña JD, García-Ríos A, Delgado-Casado N, et al. Mediterranean diet improves endothelial function in patients with diabetes and prediabetes: A report from the CORDIOPREV study. Atherosclerosis [Internet]. 2018 [citado 17/01/2022];269:50-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29274507/

13. Anikpo I, Agovi AM, Cvitanovich MJ, et al. The data-collection on adverse effects of anti-HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV. HIV Med [Internet]. 2021 [citado 17/01/2022];22(10):936-43. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290794/

14. Nobre N, Pereira M, Roine RP, et al. Factors associated with the quality of life of people living with HIV in Finland. AIDS Care [Internet]. 2017 [citado 17/01/2022];29(8):1074-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28110552/

15. Dorjee K, Choden T, Baxi SM, et al. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies. Int J Antimicrob Agents. 2018;52(5):541-53. DOI: 10.1016/j.ijantimicag.2018.07.010.

16. Pérez CE, Africano Díaz FJ, Pérez Cely HC, et al. Rol actual de los inhibidores de proteasa en el manejo del paciente VIH. Rev Infecto Médica [Internet]. 2019 [citado 17/01/2022];5(2). Disponible en: https://infectoweb.com/public/revistas/5.pdf

17. ONUSIDA. In Danger: UNAIDS Global AIDS Update 2022 [Internet]. Ginebra: ONUSIDA; 2022 [citado 08/12/2022]. Disponible en: https://www.unaids.org/en/resources/documents/2022/in-danger-global-aids-update

18. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351(9119):1881-3. DOI: 10.1016/S0140-6736(98)03391-1.

19. Ministerio de Salud. Plan Estratégico Multisectorial en VIH de Panamá 2020-2024 [Internet]. Ciudad de Panamá: Ministerio de Salud; 2019 [citado 08/12/2022]. Disponible en: https://www.minsa.gob.pa/sites/default/files/programas/plan_estrategico_multisectorial_en_vih_de_panama.pdf

20. Feinstein MJ, Nance RM, Delaney JAC, et al. Mortality following myocardial infarction among HIV-infected persons: The Center for AIDS Research Network Of Integrated Clinical Systems (CNICS). BMC Med. 2019;17(1). DOI: 10.1186/s12916-019-1385-7.

21. Baños Leyva L, León Regal ML, Mass Sosa A, et al. Estimación del riesgo cardiovascular global en hipertensos de la Universidad de Ciencias Médicas de Cienfuegos. Finlay [Internet]. 2023 [citado 03/05/2024];13(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2221-24342023000100076

22. Ho JC, Staimez LR, Narayan KMV. 1487-P: Comparison of the Framingham Risk Score, SCORE, and UKPDS Risk Engine for Predicting Cardiovascular Disease Complications in People with Diabetes. Diabetes [Internet]. 2019 [citado 08/12/2022];68(Supl 1). Disponible en: https://diabetesjournals.org/diabetes/article/68/Supplement_1/1487-P/61415

Downloads

Published

2024-07-17

How to Cite

1.
Linares-Morera A, Trimiño-Galindo L, Afonso-de-León JA, Soler-Cárdenas SF, García-Rodríguez M, Vidal-Casal JJ. Coronary risk stratification in HIV/AIDS patients treated with protease inhibitors. Rev Méd Electrón [Internet]. 2024 Jul. 17 [cited 2025 Jan. 22];46:e5176. Available from: https://revmedicaelectronica.sld.cu/index.php/rme/article/view/5176

Issue

Vol. 46 (2024)

Section

Research article

License

All content published in this journal is Open Access, distributed under the terms of the CC BY-NC 4.0 License.

It allows:

 - Copy and redistribute published material in any medium or format.

 - Adapt the content.

 This will be done under the following terms:

 - Attribute the authors' credits and indicate whether changes were made, in which case it must be in a reasonable way.

 - Non-commercial use.

 - Recognize the journal where it is published.

 The copyrights of each article are maintained, without restrictions.

Most read articles by the same author(s)

1 2 > >>